Loading clinical trials...

Comparing Immune Responses to Topical Imiquimod | Clinical Trials | Clareo Health

TERMINATED

Comparing Immune Responses to Topical Imiquimod

NCT04809662•University of California, Davis

Summary

The study is a basic science research study that is designed to characterize and compare the immune response in individuals who are designated as ABO blood group secretors, meaning they have a functional copy of the FUT2 gene versus those patients who are designated ABO non-secretors after application of topical imiquimod to these patients.

Eligibility

Age

18 - 85 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Individuals between 18 to 85 years of age
•Patients with a diagnosis that will result in treatment with imiquimod as standard of care, specifically actinic keratosis

Exclusion Criteria

•Younger than 18 years or older than 85 years.
•History of hypersensitivity/ allergic reaction or adverse reaction to imiquimod
•Individuals with a diagnostic biopsy and supportive histology of a cutaneous immune-mediated disease (e.g. psoriasis and mycosis fungoides, etc.) or diseases of the hematopoietic system, liver and the gastrointestinal tract (e.g. aplastic anemia, Crohn's disease, Ulcerative Colitis, Primary Sclerosing Cholangitis (PSC), Primary Biliary Cirrhosis, acute and chronic graft versus host disease (GVHD)).
•Individuals with autoantibodies plus objective evidence of end organ damage related to a cutaneous immune-mediated disease (e.g. psoriasis and mycosis fungoides, etc.) or diseases of the hematopoietic system, liver and the gastrointestinal tract (e.g. aplastic anemia, Crohn's disease, Ulcerative Colitis, Primary Sclerosing Cholangitis (PSC), Primary Biliary Cirrhosis, acute and chronic graft versus host disease (GVHD)).
•Individuals with a history of serious infection within the last 6 months.
•Individuals with tuberculosis, HIV, or hepatitis B, or C.
•Patients unable to provide consent
•Incarcerated individuals

Locations (1)

University of California Davis

Sacramento, California, United States

Key Dates

Start Date

March 16, 2021

Primary Completion Date

November 7, 2023

Completion Date

November 7, 2023

Last Updated

November 7, 2024

Enrollment

ACTUAL participants

Conditions

Actinic Keratoses

Interventions

Imiquimod

DRUG

Investigation of the Effect of Lipikar Baume AP+M

NCT06385340

Actinic Keratoses

View study

RECRUITING

SYsteMatical Trained learnIng aLgorithms for Oral carcInogenesiS Interpretation by Optical Coherence Tomography

NCT06321003

Oral Squamous Cell CarcinomaOral Potentially Malignant Disorder+10 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 7, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Comparing Immune Responses to Topical Imiquimod

Inclusion Criteria

Exclusion Criteria

Investigation of the Effect of Lipikar Baume AP+M

SYsteMatical Trained learnIng aLgorithms for Oral carcInogenesiS Interpretation by Optical Coherence Tomography

Combination Therapy of 5-Fluorouracil and CALcipotriol Versus 5-Fluorouracil in the Treatment of Actinic Keratosis

Effectiveness of Fractionated Laser Resurfacing to Protect Geriatric Skin From Actinic Neoplasia

The Influence of an E-learning Program on Recognition of Actinic Keratosis

Imaging Techniques to Monitor Photosensitizer and sO2 Levels During Photodynamic Therapy of Actinic Keratoses